Idylla KRAS Mutation Test

21 KRAS mutations in exons 2,3 and 4

120 minutes assay turnaround time

< 2 minutes hands-on time

Only 1 slice of FFPE tissue required

Highly sensitive & standardized

Suitable for any lab

Idylla KRAS Mutation Test (CE-IVD)

A0020/6

The fully automated Idylla^TM KRAS Mutation Test covers 21 KRAS mutations in exons 2,3 and 4 showing an excellent concordance to reference methods of >95%. Comparison with various other KRAS detecting technologies revealed a superior performance of the Idylla^TM KRAS Mutation Test in terms of ease of use, turnaround time, and hands-on time while demonstrating superior levels of sensitivity.

Download technical sheet

Specimen requirements

One of the biggest challenges in oncology biomarker testing is the ability to obtain samples of sufficient size and quality. With the Idylla^TM System only a minimal amount of sample is needed

1x 5 μm FFPE tissue section -> 50-600 mm²
1x 10 μm FFPE tissue section -> 25-300 mm²
Neoplastic cells ≥10% - if less, macrodissection is required

Clinical performance evaluation of a sensitive, rapid low-throughput test for KRAS mutation analysis using formalin-fixed, paraffin-embedded tissue samples

Weyn et al. - BMC Cancer. - February 2017

Comparison of the Idylla^TM KRAS Mutation Test to Qiagen's therascreen RGQ KRAS PCR Kit. While being highly concordant with Therascreen (96.7%), the Idylla^TM KRAS Mutation Test showed a significantly reduced invalid rate (<3% for Idylla^TM compared to 14% for therascreen).

Idylla Oncology Assays

Back to overview